<DOC>
	<DOC>NCT00876447</DOC>
	<brief_summary>The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis. This is a follow-up study to two Allergan sponsored studies (NCT00311376 and NCT00461292).</brief_summary>
	<brief_title>A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis</brief_title>
	<detailed_description>Botulinum toxin Type A 300U has been discontinued from the study. Patients remaining in the arm containing botulinum toxin Type A 300U will receive botulinum toxin Type A 200U moving forward. Also, the masking of the study is now open-label.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Trichostatin A</mesh_term>
	<criteria>Patient has participated in study 191622515 or 191622516 and the following criteria fulfilled: Patient completed at least 52 weeks in the preceding study. No longer than 6 months has elapsed since completion of the preceding study Patient has not received any prohibited medications during any intervening period between the preceding study and this longterm study. History or evidence of pelvic or urologic abnormality. Previous or current diagnosis of bladder or prostate cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>